Health TrialsbyHealthPanel

SPSIP vs ESP Block for Analgesia After Rib Fracture Surgery

ConditionsRib FracturePostoperative PainThoracic Trauma
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorAntalya City Hospital

About this trial

This randomized clinical trial aims to evaluate and compare the analgesic efficacy of the Serratus Posterior Superior Intercostal Plane (SPSIP) block and the Erector Spinae Plane (ESP) block in patients undergoing surgical stabilization of rib fractures. The primary outcome is the Visual Analog Scale (VAS) score within the first 24 hours after surgery. Secondary outcomes include total opioid consumption, requirement for rescue analgesia, block performance time, block-related and systemic side effects (hematoma, pneumothorax, local anesthetic systemic toxicity, vascular puncture, and infection), patient satisfaction assessed using a Likert scale, and quality of recovery assessed using the QoR-15 questionnaire.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients aged 18-65 years

ASA physical status I-III

Scheduled for elective video-assisted thoracoscopic surgery

Body mass index (BMI) between 18 and 35 kg/m²

Disqualifiers

Refusal to participate

Allergy to local anesthetics

Infection at the injection site

Coagulopathy or ongoing anticoagulant therapy

Trial design

Design model

Parallel

Treatments tested in this trial

  • Erector Spinae Plane Block (ESP)

    Procedure/Surgery

    Patients in this group will receive an ultrasound-guided Erector Spinae Plane Block (ESP) with 30 mL of 0.25% bupivacaine hydrochloride injected into the fascial plane between the erector spinae muscle and the fifth vertebral transverse processes, 30 minutes before surgery.

  • Serratus Posterior Superior Intercostal Plane (SPSIP)

    Procedure/Surgery

    Patients in this group will receive an ultrasound-guided Serratus Posterior Superior Intercostal Plane (SPSIP) block with 30 mL of 0.25% bupivacaine hydrochloride injected into the fascial plane between the serratus posterior superior muscle and the third rib, 30 minutes before surgery.

Treatment groups

60 Participants
are divided into 2 treatment groups
Group A: Serratus Posterior Superior Intercostal Plane Block (SPSIP)Active comparator 1 intervention
Group B: Erector Spinae Plane Block (ESP)Active comparator 1 intervention

Trial outcomes

Primary outcomes

1

Postoperative pain intensity assessed using the Visual Analog Scale (VAS)

Postoperative pain intensity (VAS score) Postoperative pain will be assessed using the visual analog scale (VAS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores represent greater pain intensity. Measurements will be recorded at predefined time points within the first 24 hours after surgery.

Time frame
0, 1, 4, 8, 12, and 24 hours after surgery

Secondary outcomes

1

Total opioid consumption via patient-controlled analgesia (PCA)

Time frame
Within the first 24 hours postoperatively
2

Requirement for rescue analgesia

Time frame
Within the first 24 hours postoperatively
3

Block performance time

Time frame
During the block procedure (intraoperative period)
4

Block-related and systemic side effects

Time frame
Within the first 24 hours postoperatively

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Antalya City Hospital

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: